Insulin Therapy in Small Animals, Part 3: Dogs.

Vet Clin North Am Small Anim Pract

Small Animal Internal Medicine, Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, 2015 Southwest 16th Avenue, Gainesville, FL 32608, USA.

Published: May 2023

Insulin therapy should ideally mimic a basal-bolus pattern. Lente, NPH, NPH/regular mixes, PZI, glargine U100, and detemir are intermediate-acting formulations that are administered twice daily in dogs. To minimize hypoglycemia, intermediate-acting insulin protocols are usually geared towards alleviating (but not eliminating) clinical signs. Insulin glargine U300 and insulin degludec meet the criteria for an effective and safe basal insulin in dogs. In most dogs, good control of clinical signs is achieved when using a basal insulin alone. In a small minority, bolus insulin at the time of at least one meal per day may be added to optimize glycemic control.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cvsm.2023.02.003DOI Listing

Publication Analysis

Top Keywords

insulin
8
insulin therapy
8
clinical signs
8
basal insulin
8
therapy small
4
small animals
4
dogs
4
animals dogs
4
dogs insulin
4
therapy ideally
4

Similar Publications

Use of Antihyperglycemic Medications Among US People with Limited English Proficiency.

J Gen Intern Med

January 2025

Department of Family Medicine, College of Human Medicine, Michigan State University, East Lansing, MI, 48824, USA.

Background: Language barriers can impact pharmaceutical disease management leading to potential health disparities among limited English proficiency (LEP) people with diabetes mellitus (DM) in the United States (US).

Objective: To assess the use of antihyperglycemic medications and estimate their impact on glycemic control by LEP status.

Design: Cross-sectional design.

View Article and Find Full Text PDF

Pancreatic β-cell damage is a critical pathological mechanism in the progression of obese type 2 diabetes mellitus (T2DM). However, the exact underlying mechanism remains unclear. We established an obese T2DM mouse model via high-fat diet feeding.

View Article and Find Full Text PDF

Background: Obesity plays a crucial role in the development of metabolic disorders including diabetes, coronary and renal diseases. There are several factors involved in the pathology of obesity, including chronic inflammation and exposure to environmental contaminants. Recently, the cholinergic co-hydrolyzing enzyme BChE has been associated with clinical conditions such as diabetes and obesity.

View Article and Find Full Text PDF

Background: Advanced glycation end-products (AGEs) can enter patients' circulation through exogenous sources, such as enteral nutrition formulae. Circulating AGEs, specifically carboxymethyllysine, can promote insulin resistance and activation of pro-inflammatory pathways leading to oxidative stress, cell death, and organ failure. Suboptimal kidney function increases the risk of elevated circulating AGEs because levels are controlled through urinary excretion.

View Article and Find Full Text PDF

Pharmacotherapy of type 1 diabetes - part 1: Yesterday.

Expert Opin Pharmacother

January 2025

The Association of Diabetes Investigators, California, CA, USA.

Introduction: Type 1 diabetes is a unique autoimmune attack on the β cell of the pancreatic islet resulting in progressive destruction of these cells and as a result the ability of the body to maintain insulin production. The consequences of insulin deficiency are very severe, and the disease was fatal prior to the ability to extract insulin from animal pancreas in 1921. We review progress in the treatment of childhood type 1 diabetes over the past 100 years.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!